SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70057 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Theresia Sarabhai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Anemia, Iron-Deficiency, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DFG Clinician Scientist Programme UMEA.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Iron deficiency anaemia (IDA) is a common comorbidity in patients with type 2 diabetes mellitus (T2DM). Sodium–glucose cotransporter‐2 inhibitors (SGLT2i) have been shown to modulate erythropoiesis and iron metabolism, but their association remains unclear. This cohort study investigated whether SGLT2i use, compared to dipeptidyl peptidase‐4 inhibitors (DPP‐4i), is associated with a lower incidence of IDA in T2DM. Materials and methods We analysed data from the IQVIA™ Disease Analyzer, a German electronic medical records database (ICD‐10) from office‐based practices. Patients with T2DM (≥18 years) who initiated SGLT2i or DPP‐4i therapy alongside metformin between 2012 and 2022 were included. Those with prior anaemia diagnoses were excluded. Propensity score matching (1:1) was performed based on age, sex, baseline HbA1c, duration of metformin use, and anaemia‐related comorbidities. Kaplan–Meier analyses and Cox proportional hazards regression models were used to compare IDA incidence between cohorts over a 5‐year follow‐up.
Results
In total 28 441 propensity score matched patients per cohort were analysed. The cumulative 5‐year incidence of IDA was significantly lower in the SGLT2i (6.9%) versus DPP‐4i cohort (11.3%) ( p < 0.001). SGLT2i use was associated with a decreased risk of IDA (HR: 0.67; 95% CI: 0.58–0.78). Subgroup analyses confirmed this association in males and elder patients (>60 years), while the protective effect was limited to metformin use under 3 years.
Conclusion
SGLT2i therapy was associated with a lower incidence of IDA in T2DM patients compared to DPP‐4i therapy. These findings suggest a potential hematologic benefit of SGLT2 inhibitors, warranting further investigation in randomised controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Epidemiology, IQVIA, Frankfurt am Main, Germany.
- University Clinic, Philipps, University, Marburg, Germany.
ORCID-Profile: Theresia Sarabhai, Karel Kostev
Förderung
- DFG Clinician Scientist Programme UMEA
Zitieren
APA
Sarabhai, T., & Kostev, K. (2025). SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70057
Vancouver
Sarabhai T, Kostev K. SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70057
BibTeX
@article{Sarabhai2025,
author = {Sarabhai, Theresia and Kostev, Karel},
title = {SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70057}
}
EUVIMED